Call us today 855-494-4867

For Patients

Call us today 855-494-4867

Greenbrook Logo

Resources

Learn more about what Greenbrook can offer you and your patient

NeuroStar TMS Therapy

NeuroStar TMS (Transcranial Magnetic Stimulation) therapy is a FDA-cleared, non-medicated treatment for those with Major Depressive Disorder and Obsessive Compulsive Disorder.

  • TMS at a Glance

  • How does NeuroStar TMS work?

    Unlike medications, which affect the entire body as they pass through the blood-brain barrier, NeuroStar TMS therapy targets depression at the source. It works via magnetic pulses that induce electrical currents, stimulating neurons for a therapeutic effect. 

    Learn more
  • Who is a NeuroStar TMS candidate?

    NeuroStar TMS (Transcranial Magnetic Stimulation) therapy is FDA-cleared for people 15 years of age and older with Major Depressive Disorder (MDD) and Obsessive Compulsive Disorder (OCD) who have failed to achieve satisfactory improvement from previous antidepressant medication treatment.

    Learn more
  • When is NeuroStar TMS indicated?

    Research indicates that 83% of patients experience at least a 50% reduction in depressive symptoms after treatment, with 62% achieving remission and nearly complete relief. In one study, 62.5% of those who saw improvement continued to see positive results or remained in remission a year later. 

    When is it indicated?
  • NeuroStar TMS therapy for OCD

    NeuroStar TMS is an FDA-cleared treatment option for Obsessive-Compulsive Disorder. The OCD protocol has key technical differences than MDD protocol, including different pattern of stimulation targeting the medial prefrontal cortex.

    Learn more
  • SPRAVATO® Esketamine at a Glance

  • How does SPRAVATO® work?

    Traditional antidepressants are believed to work by boosting serotonin and other neurotransmitters, which then influence glutamate—a brain chemical that helps regulate mood and depression. SPRAVATO® uses esketamine, and is thought to directly target the glutamate system, activating receptors that promote the formation of new pathways in the brain. Although SPRAVATO® is FDA-approved for treatment-resistant depression and for alleviating depressive symptoms in adults with major depressive disorder who experience suicidal thoughts or actions, researchers are actively studying its full impact. 

  • Who is a Spravato® candidate?

    SPRAVATO® esketamine nasal spray is FDA-approved for people with depression who have not experienced adequate improvement with antidepressant medications.

  • Who shouldn't take SPRAVATO®?

    Greenbrook recommends calling for more information on whether treatment is right for your patient. Below are some of the common contraindications, but each patient's journey is unique.

    • Uncontrolled hypertension
    • History of stroke or brain bleeds
    • Abnormal blood vessels at risk of bleeding, such as aneurysms or arteriovenous malformations (AVMs)
    • Sensitivity to esketamine or ketamine

    View Indications and Important Safety Information.

SPRAVATO®

SPRAVATO® is an FDA-approved esketamine nasal spray, a refined form of ketamine, used to treat adults with treatment-resistant depression and depressive symptoms in adults with major depressive disorder (MDD) with suicidal thoughts or actions.

What can your patient expect when doing treatment?

Patient Journey

Learn about our treatments

After you refer your patient our team will schedule them a no-cost consultation with one of our Consult Coordinators. The Consult Coordinator will review their history and explain aspects of our treatments.


The Consult Coordinator will also explain treatment payment options, including going over standard insurance plan criteria with your patient.

Find out if treatment is right for your patient

Next, your patient will meet with a Greenbrook affiliated licensed provider for an evaluation which includes questions about your patient's history and symptoms.


If the provider has determined that your patient is a candidate for treatment and they are ready to move forward, our team will create an individualized treatment plan.

Starting treatment

Typical treatment course of NeuroStar TMS therapy

  • 5 treatments a week
  • 6-9 weeks
  • 18-45 minute treatments
  • 30-36 total sessions

Average SPRAVATO® treatment course

A typical round of esketamine nasal spray treatment is broken up into three phases: 

  • Induction, Week 1-4: 2 treatments each week 
  • Maintenance, Week 5-8: 1 treatment each week
  • Maintenance, Week 9+: 1 treatment every 1-2 weeks

Treatment plans may vary depending on clinical conditions. 

Greenbrook TMS Provider team

Our Care Team is here for you & your patients

Learn about Greenbrook

Hear Real Stories from Real Patients

By Daniel Hageman April 12, 2022
Joseph’s TMS Journey
By Daniel Hageman April 12, 2022
Sam’s TMS Journey
By Daniel Hageman April 12, 2022
Sarah’s TMS Journey
By Daniel Hageman April 12, 2022
Dereck’s TMS Journey
Show More

Do you have a patient who would benefit from treatment with us?

Help them get started today.

Refer a Patient
Share by: